R/Pharma Round Tables
We’re just a couple of days out from the R/Pharma round tables!
With the help of an advisory board spanning Amgen, BeiGene, Genentech, GSK, The Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis, Pfizer, The Prostate Cancer Clinical Trials Consortium (PCCTC), Roche and Posit PBC the following topics are now on the agenda for our round tables (our attempt at paraphrasing these nuanced topics):
- Can we stop validating R packages internally, and build a pan-industry process?
- How can we help the path to interactive regulatory submissions?
- What’s needed to be more confident depending on externally governed packages?
- Can we combine our learnings on making a case for OS contributions?
- Where is the potential for impact with LLMs/AA/AI for both drug development, and data scientist efficiency?
- Where are we as data scientists and SCE developers on multi-modal, multi-disciplinary, drug development?
and probably the topic we are most excited about (especially with Roche and others attending, to discuss its SCE for CT/RWE and PHC) is…
- What is a modern workflow? What are the key capabilities of a modern SCE? What can we learn from each other enabling diversity without compromising our SCE architecture - from legacy codebases/languages and their workflows built around mounted drives and unix permissions, through to multi-modal analyses querying multiple data stores via tokens as secrets, mixing not just open source languages, but different dockerfiles in a single analysis.
70 representatives from 42 companies will come together to tackle these and other questions.
Review the agenda below, or visit the discussion link to see the proposed topics: